

## Drugs for non-serious diseases (C)

ATC	Products	Active Substances	Therapeutic indications	Authorisation date (EU)	Available treatments	Superiority (only if available treatments = C)	Therapeutic effect	Therapeutic innovation
D11AX	<u>Protopy</u> , ( <u>Protopic</u> )	Tacrolimus	Tacrolimus 0.03% ointment: Treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies. Treatment of moderate to severe atopic dermatitis in children (2 years of age and above)	28-feb-02	B		A	A
G04BE	<u>Patrex</u> , ( <u>Viagra</u> )	Sildenafil	Treatment of erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. In order for PATREX to be effective, sexual stimulation is required. PATREX is not indicated for use by women	15/09/1998, (14/09/1998)	A		A	A
D06BB	<u>Aldara</u>	Imiquimod	Imiquimod cream is indicated for the topical treatment of external genital and perianal warts (condylomata <input type="checkbox"/> cuminata) in adult patients.	18 Sep 1998	C	C1	A	B
G03GA	<u>Luveris</u>	Lutropin Alfa*	Luveris in association with a follicle stimulating hormone (FSH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH	29-nov-00	C	C2	A	Pharm
G04BE	<u>Taluvian</u> , ( <u>Ixense</u> ), ( <u>Uprima</u> )	Apomorphine Hydrochloride	Treatment of erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. In order for Apomorphine hydrochloride Abbott Laboratories Ltd to be effective, sexual stimulation is required. Apomorphine hydrochloride Abbott Laboratories Ltd is not indicated for use by women.	28-mag-01	C	C2	A	Pharm
G04BE	<u>Cialis</u>	Tadalafil	Treatment of erectile dysfunction. In order for CIALIS to be effective, sexual stimulation is required. CIALIS is not indicated for use by women.	12-nov-02	C	C2	A	Pharm
G04BE	<u>Vivanza</u> , ( <u>Levitra</u> )	Vardenafil	Treatment of erectile dysfunction, which is the inability to achieve or maintain a penile reaction sufficient for satisfactory sexual performance	04/03/2003, (06/03/2003)	C	C2	A	Pharm
N05CF	<u>Sonata</u> , ( <u>Zerene</u> )	Zaleplon	Sonata is indicated for the treatment of patients with insomnia who have difficulty falling asleep. It is indicated only when the disorder is severe, disabling or subjecting the individual to extreme distress.	12-mar-99	C	C2	A	Pharm
J05AH	<u>Tamiflu</u>	Oseltamivir	Treatment of influenza in adults and children one year of age or older, who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of onset	20-giu-02	C	C2	B	Pharm
D11AX	<u>Vaniqa</u>	Eflornithine	Treatment of facial hirsutism in women	20-mar-01	C	C2	C	Pharm
G03GA	<u>GONAL-f</u>	Follitropin Alfa*	Anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate. -Stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (AR)	20-ott-95	C	C3	A	Tech

ATC	Products	Active Substances	Therapeutic indications	Authorisation date (EU)	Available treatments	Superiority (only if available treatments = C)	Therapeutic effect	Therapeutic innovation
G03GA	<u>Puregon</u>	Follitropin-Beta*	In the female: Puregon is indicated for the treatment of female infertility in the following clinical situations: -Anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate. -Controll	03-mag-96	C	C3	A	Tech
G03GA	<u>Ovitrelle</u>	Choriogonadotrophin Alfa*	Ovitrelle is indicated in the treatment of: (i) Women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): Ovitrelle is administered to trigger final follicular maturation and luteinisation after st	02-feb-01	C	C3	A	Tech
H01CC	<u>Cetrotide</u>	Cetrorelix (As Acetate)	Prevention of premature ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques. In clinical trials Cetrotide 0.25 mg was used with human menopausal gonadotropin (HMG), however, li	13-apr-99	C	C3	A	Tech
H01CC	<u>Orgalutran</u>	Ganirelix	The prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART). In clinical trials Orgalutran was used with recombinant human follicle stimulating hormon	17-mag-00	C	C3	A	Tech
M01AH	<u>Rayzon</u> , <u>(Dynastat)</u> , <u>(Xapit)</u>	Parecoxib	For the short-term treatment of postoperative pain	22-mar-02	C	C3	A	Tech
R06AX	<u>Neoclarityn</u> , <u>(Aerius)</u> , <u>(Alex)</u> , <u>(Opulis)</u> , <u>(Azomyr)</u>	Desloratadine	Neoclarityn is indicated for the relief of symptoms associated with: - allergic rhinitis (AR) - chronic idiopathic urticaria (CIU)	15-gen-01	C	C3	A	Tech
S01GX	<u>Emadine</u>	Emedastine	Symptomatic treatment of seasonal allergic conjunctivitis	27-gen-99	C	C3	A	Tech
S01GX	<u>Opatanol</u>	Olopatadine	Treatment of ocular signs and symptoms of seasonal allergic conjunctivitis	17-mag-02	C	C3	A	Tech

\* Biotechnological developed drugs (SEE ANNEX PART "A" - EEC 2309/93)

\*\* Drugs approved in special circumstances